{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:29:29Z","timestamp":1768548569571,"version":"3.49.0"},"posted":{"date-parts":[[2020,6,5]]},"group-title":"Oncology","reference-count":40,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New York.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-white. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (24%) and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (&gt;70 years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p&lt;0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p&lt;0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-white race, and mortality. Ninety-six percent (22\/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia were associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM patients who need early intervention to improve outcome in future outbreaks of COVID-19.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2020.06.04.20122846","type":"posted-content","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T06:29:32Z","timestamp":1591424972000},"source":"Crossref","is-referenced-by-count":4,"title":["A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-0994","authenticated-orcid":false,"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-197X","authenticated-orcid":false,"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane Marie","family":"Del Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-9520","authenticated-orcid":false,"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-9690","authenticated-orcid":false,"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021010522551207000_2020.06.04.20122846v2.1","unstructured":"Richardson S , Hirsch JS , Narasimhan M , et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020."},{"key":"2021010522551207000_2020.06.04.20122846v2.2","unstructured":"https:\/\/covid19tracker.health.ny.gov\/"},{"key":"2021010522551207000_2020.06.04.20122846v2.3","unstructured":"Robilotti EV , Babady NE , Mead PA , et al. Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv 2020:2020.05.04.20086322."},{"key":"2021010522551207000_2020.06.04.20122846v2.4","doi-asserted-by":"crossref","unstructured":"Dai M , Liu D , Liu M , et al. Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020.","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"2021010522551207000_2020.06.04.20122846v2.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"2021010522551207000_2020.06.04.20122846v2.6","doi-asserted-by":"crossref","unstructured":"Yu J , Ouyang W , Chua MLK , Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncology 2020.","DOI":"10.1101\/2020.02.22.20025320"},{"key":"2021010522551207000_2020.06.04.20122846v2.7","doi-asserted-by":"crossref","unstructured":"Zhang L , Zhu F , Xie L , et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020.","DOI":"10.1016\/j.annonc.2020.03.296"},{"key":"2021010522551207000_2020.06.04.20122846v2.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"2021010522551207000_2020.06.04.20122846v2.9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-40320-5_12","article-title":"Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma","volume":"169","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2021010522551207000_2020.06.04.20122846v2.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0868"},{"key":"2021010522551207000_2020.06.04.20122846v2.11","unstructured":"Ingraham NE , Lotfi-Emran S , Thielen BK , et al. Immunomodulation in COVID-19. The Lancet Respiratory Medicine."},{"key":"2021010522551207000_2020.06.04.20122846v2.12","doi-asserted-by":"crossref","unstructured":"Mehta P , McAuley DF , Brown M , et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"2021010522551207000_2020.06.04.20122846v2.13","doi-asserted-by":"crossref","unstructured":"Merad M , Martin JC . Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology 2020.","DOI":"10.1038\/s41577-020-0353-y"},{"key":"2021010522551207000_2020.06.04.20122846v2.14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy","volume":"11","year":"2018","journal-title":"Journal of Hematology & Oncology"},{"key":"2021010522551207000_2020.06.04.20122846v2.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2021010522551207000_2020.06.04.20122846v2.16","doi-asserted-by":"crossref","unstructured":"Zhang C , Wu Z , Li J-W , Zhao H , Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International Journal of Antimicrobial Agents 2020:105954.","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"2021010522551207000_2020.06.04.20122846v2.17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2021010522551207000_2020.06.04.20122846v2.18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2021010522551207000_2020.06.04.20122846v2.19","doi-asserted-by":"crossref","unstructured":"Gong J , Dong H , Xia SQ , et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. medRxiv 2020:2020.02.25.20025643.","DOI":"10.1101\/2020.02.25.20025643"},{"key":"2021010522551207000_2020.06.04.20122846v2.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2021010522551207000_2020.06.04.20122846v2.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2021010522551207000_2020.06.04.20122846v2.22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","year":"2016","journal-title":"European Journal of Haematology"},{"key":"2021010522551207000_2020.06.04.20122846v2.23","doi-asserted-by":"crossref","first-page":"e0200043","DOI":"10.1371\/journal.pone.0200043","article-title":"In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals","volume":"13","year":"2018","journal-title":"PloS one"},{"key":"2021010522551207000_2020.06.04.20122846v2.24","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.bbrc.2018.07.112","article-title":"KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis","volume":"503","year":"2018","journal-title":"Biochemical and biophysical research communications"},{"key":"2021010522551207000_2020.06.04.20122846v2.25","doi-asserted-by":"crossref","unstructured":"Al Saleh AS , Sher T , Gertz MA . Multiple Myeloma in the Time of COVID-19. Acta haematologica 2020:1\u20137.","DOI":"10.1159\/000507690"},{"key":"2021010522551207000_2020.06.04.20122846v2.26","unstructured":"Society IM . Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. 2020."},{"key":"2021010522551207000_2020.06.04.20122846v2.27","doi-asserted-by":"crossref","unstructured":"Malard F , Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. The Lancet Haematology 2020.","DOI":"10.1016\/S2352-3026(20)30124-1"},{"key":"2021010522551207000_2020.06.04.20122846v2.28","unstructured":"COVID-19: Data. 2020. at https:\/\/www1.nyc.gov\/site\/doh\/covid\/covid-19-data.page.)"},{"key":"2021010522551207000_2020.06.04.20122846v2.29","unstructured":"Cook G , Ashcroft AJ , Pratt G , et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy. British Journal of Haematology;n\/a."},{"key":"2021010522551207000_2020.06.04.20122846v2.30","doi-asserted-by":"crossref","unstructured":"Gross CP , Essien UR , Pasha S , Gross JR , Wang S-y , Nunez-Smith M. Racial and Ethnic Disparities in Population Level Covid-19 Mortality. medRxiv 2020:2020.05.07.20094250.","DOI":"10.1101\/2020.05.07.20094250"},{"key":"2021010522551207000_2020.06.04.20122846v2.31","doi-asserted-by":"crossref","unstructured":"Henning-Smith C , Tuttle M , Kozhimannil KB . Unequal Distribution of COVID-19 Risk among Rural Residents by Race and Ethnicity. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2020.","DOI":"10.1111\/jrh.12463"},{"key":"2021010522551207000_2020.06.04.20122846v2.32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/jgs.14472","article-title":"Racial Differences in the Incidence of Cardiovascular Risk Factors in Older Black and White Adults","volume":"65","year":"2017","journal-title":"Journal of the American Geriatrics Society"},{"key":"2021010522551207000_2020.06.04.20122846v2.33","doi-asserted-by":"crossref","unstructured":"Diane Marie Del Valle M , Seunghee Kim-Schulze PD , Hsin-Hui Huang PD , et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. MEDRXIV 2020;115758.","DOI":"10.1101\/2020.05.28.20115758"},{"key":"2021010522551207000_2020.06.04.20122846v2.34","doi-asserted-by":"crossref","unstructured":"Jatiani SS , Aleman A , Madduri D , et al. Myeloma CAR-T CRS Management with IL-1R Antagonist Anakinra. Clinical Lymphoma Myeloma and Leukemia 2020.","DOI":"10.1016\/j.clml.2020.04.020"},{"key":"2021010522551207000_2020.06.04.20122846v2.35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"2021010522551207000_2020.06.04.20122846v2.36","doi-asserted-by":"crossref","unstructured":"Costa LJ WS , Berm\u00fadez A. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Abstract #143. American Society of Hematology. Orlando, FL: ASH Annual Meeting Proceedings; 2019.","DOI":"10.1182\/blood-2019-122895"},{"key":"2021010522551207000_2020.06.04.20122846v2.37","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.4049\/jimmunol.174.12.7977","article-title":"Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection","volume":"174","year":"2005","journal-title":"The Journal of Immunology"},{"key":"2021010522551207000_2020.06.04.20122846v2.38","doi-asserted-by":"crossref","unstructured":"Bryce C , Grimes Z , Pujadas E , et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv 2020:2020.05.18.20099960.","DOI":"10.1101\/2020.05.18.20099960"},{"key":"2021010522551207000_2020.06.04.20122846v2.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"2021010522551207000_2020.06.04.20122846v2.40","doi-asserted-by":"crossref","unstructured":"Cao Y , Wei J , Zou L , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology 2020.","DOI":"10.1016\/j.jaci.2020.05.019"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.06.04.20122846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:43:22Z","timestamp":1768484602000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.06.04.20122846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1101\/2020.06.04.20122846","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13045-020-00934-x","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2020,6,5]]},"subtype":"preprint"}}